High Dose CHOP in Lymphoma

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rambam Health Care Campus
• Treatments: Cyclophosphamide

Criteria

Inclusion Criteria:

• large-cell non-Hodgkin's lymphoma

• IPI low-intermediate, high-intermediate and high or bulky mediastinum

• age 18-65

Exclusion Criteria:

• previous treatment for lymphoma

• serious concurrent systemic disease